ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Pass Above 50 Day Moving Average – Here’s What Happened

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $90.03 and traded as high as $99.53. ProShares Ultra Nasdaq Biotechnology shares last traded at $99.53, with a volume of 5,066 shares trading hands.

ProShares Ultra Nasdaq Biotechnology Trading Up 2.9%

The firm has a market cap of $83.61 million, a P/E ratio of 20.68 and a beta of 1.19. The firm’s 50 day moving average is $90.03 and its two-hundred day moving average is $85.58.

Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in BIB. Kaizen Financial Strategies grew its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 4.7% in the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock valued at $483,000 after buying an additional 250 shares during the period. Citadel Advisors LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 3rd quarter worth $307,000. Finally, Franklin Resources Inc. acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth $32,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.